Acquisition Opportunity Mapi Group has been acquired by ICON plc, presenting potential integration and cross-sell opportunities across ICON's late-phase services, market access, and patient-centered outcomes capabilities.

Global Reach With presence in 130 countries through Mapi Group and its networks, there is a scalable path to expand ICON’s or partner offerings into additional markets and leverage local insights for market access and health economics research.

Late Phase Synergy Leverage Mapi Group’s strength in Global Late Phase Research and Linguistic Validation to enhance ICON’s late-phase execution, eCOA deployments, and patient-centric outcome validation.

Patient-Centric Leverage Mapi’s patient-centered outcomes resources and Mapi Research Trust can be packaged to strengthen ICON’s value proposition around patient-reported outcomes, real-world evidence, and payer engagement.

Cross-Sell Contours Current revenue focus aligns with mid-to-large pharma and CRO competitors; there is an opportunity to cross-sell combined capabilities to similar clients seeking integrated market access, health economics, and translational research services.